{"hands_on_practices": [{"introduction": "The design of any effective lentiviral vector begins with a critical question: will the therapeutic payload fit? The viral capsid has a finite volume, imposing a strict upper limit on the length of the RNA genome that can be efficiently packaged. This exercise [@problem_id:5017619] models this fundamental constraint, tasking you with a core calculation that every vector biologist must perform to ensure a proposed design is physically viable before proceeding with costly and time-consuming cloning and production.", "problem": "A self-inactivating Human Immunodeficiency Virus type 1 (HIV-1) lentiviral vector used in translational medicine packages a single-stranded RNA genome whose total length is constrained by efficient encapsidation mechanisms. Empirically, efficient packaging declines for total genome lengths near the wild-type Human Immunodeficiency Virus type 1 (HIV-1) genome size, approximately $9$â€“$10$ kilobases (kb). For this calculation, define the threshold for efficient packaging as a capacity $L_{\\text{cap}} = 9{,}700$ base pairs (bp). The transcribed vector backbone (excluding the therapeutic payload) has a length $L_{\\text{backbone}} = 6{,}000$ bp. A clinical-grade therapeutic payload comprises a promoter, a coding complementary DNA (cDNA), a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE), and a polyadenylation signal (polyA), with the following lengths: promoter $= 1{,}200$ bp, cDNA $= 1{,}489$ bp, WPRE $= 600$ bp, and polyA $= 250$ bp.\n\nUsing the facts that nucleotide sequence lengths add linearly along the genome, and that $1$ kilobase equals $1{,}000$ base pairs, compute the efficiency margin, defined as\n$$\\Delta = L_{\\text{cap}} - \\left(L_{\\text{backbone}} + L_{\\text{promoter}} + L_{\\text{cDNA}} + L_{\\text{WPRE}} + L_{\\text{polyA}}\\right),$$\nexpressed in kilobases. A positive $\\Delta$ indicates the payload fits within the efficient packaging capacity, while a negative $\\Delta$ indicates it exceeds the capacity threshold. Round your final numerical answer to four significant figures and express it in kb.", "solution": "The user provides a problem that requires the calculation of an \"efficiency margin\" for a lentiviral vector used in gene therapy. The problem must first be validated for scientific and logical soundness.\n\n### Step 1: Extract Givens\nThe problem statement provides the following definitions and values:\n- Threshold for efficient packaging capacity: $L_{\\text{cap}} = 9{,}700$ base pairs (bp).\n- Length of the vector backbone: $L_{\\text{backbone}} = 6{,}000$ bp.\n- Length of the promoter: $L_{\\text{promoter}} = 1{,}200$ bp.\n- Length of the coding complementary DNA (cDNA): $L_{\\text{cDNA}} = 1{,}489$ bp.\n- Length of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE): $L_{\\text{WPRE}} = 600$ bp.\n- Length of the polyadenylation signal (polyA): $L_{\\text{polyA}} = 250$ bp.\n- Conversion factor: $1$ kilobase (kb) $= 1{,}000$ base pairs (bp).\n- Definition of the efficiency margin, $\\Delta$:\n$$ \\Delta = L_{\\text{cap}} - \\left(L_{\\text{backbone}} + L_{\\text{promoter}} + L_{\\text{cDNA}} + L_{\\text{WPRE}} + L_{\\text{polyA}}\\right) $$\n- The final answer is required in kilobases (kb) and must be rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is subjected to validation against the required criteria.\n- **Scientifically Grounded**: The problem is grounded in established principles of molecular biology and virology, specifically concerning the design of lentiviral vectors for gene therapy. The packaging limit of lentiviruses is a critical real-world constraint. The listed vector components (promoter, cDNA, WPRE, polyA) are standard elements of a gene expression cassette. The specified lengths are realistic for such components. The premise is factually correct and scientifically sound.\n- **Well-Posed**: The problem is well-posed. It provides all necessary numerical data and a clear, explicit formula for the quantity to be calculated. The objective is unambiguous, leading to a unique solution.\n- **Objective**: The language is precise, quantitative, and free of subjective or opinion-based statements. All terms are clearly defined.\n\nThe problem does not exhibit any flaws. It is scientifically sound, fully specified, internally consistent, and requires a direct application of the provided formula and principles.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. A solution will be computed.\n\nThe solution proceeds by first calculating the total length of the single-stranded RNA genome that is to be packaged into the viral particle. This total length, which we will denote as $L_{\\text{total}}$, is the sum of the length of the vector backbone and the lengths of all components of the therapeutic payload.\n\nThe total length of the therapeutic payload, $L_{\\text{payload}}$, is given by the sum of its constituent parts:\n$$ L_{\\text{payload}} = L_{\\text{promoter}} + L_{\\text{cDNA}} + L_{\\text{WPRE}} + L_{\\text{polyA}} $$\nSubstituting the given values:\n$$ L_{\\text{payload}} = 1{,}200 \\text{ bp} + 1{,}489 \\text{ bp} + 600 \\text{ bp} + 250 \\text{ bp} = 3{,}539 \\text{ bp} $$\n\nThe total genome length, $L_{\\text{total}}$, is the sum of the backbone and the payload:\n$$ L_{\\text{total}} = L_{\\text{backbone}} + L_{\\text{payload}} $$\n$$ L_{\\text{total}} = 6{,}000 \\text{ bp} + 3{,}539 \\text{ bp} = 9{,}539 \\text{ bp} $$\n\nNow, we can compute the efficiency margin, $\\Delta$, using the provided definition:\n$$ \\Delta = L_{\\text{cap}} - L_{\\text{total}} $$\nSubstituting the values for the capacity and the total length, both in base pairs:\n$$ \\Delta = 9{,}700 \\text{ bp} - 9{,}539 \\text{ bp} = 161 \\text{ bp} $$\nThe result, $\\Delta = 161 \\text{ bp}$, is positive, which indicates that the total genome length is within the efficient packaging capacity.\n\nThe problem requires the final answer to be expressed in kilobases (kb). We use the given conversion factor, $1 \\text{ kb} = 1{,}000 \\text{ bp}$.\n$$ \\Delta \\text{ (in kb)} = \\frac{161 \\text{ bp}}{1{,}000 \\text{ bp/kb}} = 0.161 \\text{ kb} $$\n\nFinally, the problem requires the answer to be rounded to four significant figures. The number $0.161$ has three significant figures (the digits $1$, $6$, and $1$). To express this with four significant figures, a trailing zero must be added.\n$$ \\Delta = 0.1610 \\text{ kb} $$\nThis result represents the remaining capacity within the viral vector after incorporating the specified payload.", "answer": "$$\\boxed{0.1610}$$", "id": "5017619"}, {"introduction": "A key challenge in translating gene therapy to the clinic is accurately measuring a vector's potency. While techniques can count the total number of physical viral particles, not every particle is functional. This exercise [@problem_id:5017554] guides you through deriving the theoretical relationship between physical particles and biologically active \"transducing units,\" and then applying this model to pinpoint the specific molecular and cellular steps that most significantly reduce a vector's functional efficacy.", "problem": "A translational medicine laboratory is optimizing a Lentiviral Vector (LV) for gene therapy. Two complementary measurements of vector quality are used: a physical particle concentration measured by Nanoparticle Tracking Analysis (NTA) and a functional titer measured as Transducing Units per milliliter (TU/mL) using a target-cell assay that scores cells expressing a reporter after a single round of transduction.\n\nStarting from first principles appropriate to independent rare-event processes, assume that each physical particle is an independent trial with a net per-particle success probability that a single particle ultimately yields a stably expressing target cell under the assay conditions. Use the following foundations only: independence of trials, the Poisson model for the number of rare successful events per cell, and the definition that the fraction of positive cells at readout is given by $1 - \\exp(-m)$ when the per-cell mean number of successful events is $m$. Using these bases and the operational definition of TU/mL as the functional quantity that reproduces the same fraction of positive cells under the same exposure conditions, construct an analytic relationship among the physical particle concentration $N_p$ (particles/mL), the net per-particle success probability $p_s$, and the functional titer $T$ (TU/mL). Do not invoke any additional untested assumptions.\n\nNow consider the following experimentally grounded decomposition of the per-particle success probability $p_s$ into stepwise efficiencies (each expressed as a probability between $0$ and $1$) under the specific assay used to define TU/mL:\n- Fraction of particles that contain a full-length vector RNA genome: $p_g = 0.82$.\n- Fraction of particles that display a functional envelope glycoprotein: $p_{\\text{env}} = 0.88$.\n- Net probability over the exposure time that an envelope-competent particle will encounter a target cell and fuse: $p_{\\text{enc}} = 0.08$.\n- Probability of successful reverse transcription: $p_{\\text{rt}} = 0.75$.\n- Probability of successful nuclear import of preintegration complexes: $p_{\\text{imp}} = 0.85$.\n- Probability of successful integration: $p_{\\text{int}} = 0.55$.\n- Probability that integrated provirus expresses above the assay threshold at readout: $p_{\\text{expr}} = 0.92$.\n- Probability that the assay detects an expressing cell (analytical sensitivity): $p_{\\text{det}} = 0.97$.\n\nAssume these steps are conditionally independent in sequence so that $p_s$ is the product of the above terms. The NTA measurement gives a physical particle concentration of $N_p = 2.4 \\times 10^{11}$ particles/mL.\n\nUsing only the relationship you derive and the data provided, compute the predicted functional titer $T$ in Transducing Units per milliliter. Round your answer to three significant figures and express the final result in TU/mL. Additionally, in your derivation and reasoning, identify at least two mechanistic contributors from the stepwise model that dominate the discrepancy between physical particles and functional units, and justify why they exert strong leverage on the particle-to-TU gap under typical assay conditions. Your final numerical answer should be a single real number corresponding to the predicted $T$; report it as a dimensionless number, but interpret it as TU/mL as instructed above.", "solution": "The problem is found to be valid upon critical examination. It is scientifically grounded in the principles of virology and biostatistics, well-posed with sufficient information for a unique solution, and objective in its formulation. The problem asks for the derivation of a relationship, a numerical calculation based on that derivation, and an interpretation of the contributing factors.\n\n**Part 1: Derivation of the relationship between $N_p$, $p_s$, and $T$**\n\nWe begin from the first principles stipulated in the problem. The core assumption is that viral transduction of a cell is a rare-event process, which is well-modeled by the Poisson distribution.\n\nLet $m$ be the mean number of successful transduction events per target cell. The problem statement provides the fundamental relationship that the fraction of positive (transduced) cells, $F$, is given by:\n$$F = 1 - \\exp(-m)$$\nThis formula arises from the Poisson distribution, where the probability of a cell receiving zero successful transductions is $P(k=0) = \\frac{m^0 \\exp(-m)}{0!} = \\exp(-m)$. The fraction of cells with at least one transduction is therefore $1 - P(k=0) = 1 - \\exp(-m)$.\n\nWe can express $m$ in two ways, based on the physical and functional descriptions of the vector stock.\n\nFirst, consider the physical particle perspective. Let $V$ be a volume of the vector stock (in mL) added to a culture containing $C$ target cells.\nThe total number of physical particles added is $N_{total} = N_p \\times V$, where $N_p$ is the physical particle concentration in particles/mL.\nThe mean number of physical particles per cell is $\\frac{N_{total}}{C} = \\frac{N_p V}{C}$.\nEach physical particle is an independent trial with a net success probability $p_s$ of causing a stable transduction event.\nTherefore, the mean number of *successful* events per cell, $m$, is the product of the mean number of physical particles per cell and the success probability per particle:\n$$m = \\left(\\frac{N_p V}{C}\\right) p_s$$\n\nSecond, consider the functional titer perspective. The functional titer, $T$, is given in Transducing Units per mL (TU/mL). By its operational definition, a \"Transducing Unit\" is a hypothetical particle that is guaranteed to cause a successful event. The titer $T$ is thus the concentration of these functional units.\nWhen a volume $V$ of the vector stock is added, the total number of TUs added is $T \\times V$.\nThe mean number of functional units per cell is, by this definition, the functional multiplicity of infection (MOI), which is our same quantity $m$:\n$$m = \\frac{T V}{C}$$\n\nThe problem states that $T$ is defined as the functional quantity that reproduces the same fraction of positive cells under the same conditions. This allows us to equate the two expressions for $m$:\n$$\\left(\\frac{N_p V}{C}\\right) p_s = \\frac{T V}{C}$$\nThe experimental parameters $V$ (volume of vector added) and $C$ (number of cells) are common to both conceptual frameworks and cancel from the equation, yielding a fundamental relationship independent of specific assay conditions:\n$$N_p p_s = T$$\nThis derived relationship states that the functional titer ($T$) is equal to the physical particle concentration ($N_p$) multiplied by the net probability ($p_s$) that a single physical particle is functionally competent to complete all steps required for successful transduction and detection.\n\n**Part 2: Calculation of the Functional Titer $T$**\n\nThe net success probability $p_s$ is given as the product of the probabilities of conditionally independent steps:\n$$p_s = p_g \\times p_{\\text{env}} \\times p_{\\text{enc}} \\times p_{\\text{rt}} \\times p_{\\text{imp}} \\times p_{\\text{int}} \\times p_{\\text{expr}} \\times p_{\\text{det}}$$\nSubstituting the given numerical values:\n$$p_s = (0.82) \\times (0.88) \\times (0.08) \\times (0.75) \\times (0.85) \\times (0.55) \\times (0.92) \\times (0.97)$$\nCalculating the product:\n$$p_s = (0.7216) \\times (0.08) \\times (0.75) \\times (0.85) \\times (0.55) \\times (0.92) \\times (0.97)$$\n$$p_s = (0.057728) \\times (0.75) \\times (0.85) \\times (0.55) \\times (0.92) \\times (0.97)$$\n$$p_s = (0.043296) \\times (0.85) \\times (0.55) \\times (0.92) \\times (0.97)$$\n$$p_s = (0.0368016) \\times (0.55) \\times (0.92) \\times (0.97)$$\n$$p_s = (0.02024088) \\times (0.92) \\times (0.97)$$\n$$p_s = (0.0186216096) \\times (0.97)$$\n$$p_s \\approx 0.0180629613$$\nNow, we use the derived relationship $T = N_p p_s$ to compute the functional titer $T$. The physical particle concentration is given as $N_p = 2.4 \\times 10^{11}$ particles/mL.\n$$T = (2.4 \\times 10^{11}) \\times (0.0180629613)$$\n$$T \\approx 4.3351107 \\times 10^9 \\text{ TU/mL}$$\nThe problem requires rounding the final answer to three significant figures.\n$$T \\approx 4.34 \\times 10^9 \\text{ TU/mL}$$\n\n**Part 3: Identification of Dominant Mechanistic Contributors to the Particle-to-TU Gap**\n\nThe discrepancy between the physical particle count ($N_p$) and the functional titer ($T$) is quantified by the ratio $N_p/T$, which is equal to $1/p_s$. In this case, $1/p_s \\approx 1/0.01806 \\approx 55$. This means there are approximately $55$ physical particles for every $1$ transducing unit. This large gap is due to the cumulative inefficiencies of the transduction process. The dominant contributors to this gap are the steps with the lowest probabilities, as they act as the most severe bottlenecks.\n\nThe given probabilities are:\n$p_g = 0.82$, $p_{\\text{env}} = 0.88$, $p_{\\text{enc}} = 0.08$, $p_{\\text{rt}} = 0.75$, $p_{\\text{imp}} = 0.85$, $p_{\\text{int}} = 0.55$, $p_{\\text{expr}} = 0.92$, $p_{\\text{det}} = 0.97$.\n\nBy inspection, the two smallest probabilities are:\n1.  **$p_{\\text{enc}} = 0.08$**: The probability that an envelope-competent particle will encounter a target cell and fuse. This is a major bottleneck because it involves stochastic physical processes. A virion must travel via Brownian motion through the culture medium to come into proximity with a cell, successfully bind to a specific surface receptor, and then execute membrane fusion. This multi-step process is highly inefficient in a static culture system, where the timescale of the assay is limited. This step represents the transition from a three-dimensional random search in the fluid volume to a two-dimensional interaction on the cell surface, which inherently has a low probability of success for any given particle.\n\n2.  **$p_{\\text{int}} = 0.55$**: The probability of successful integration into the host genome. Even after a virus has successfully entered the cell, reverse-transcribed its RNA genome into DNA, and transported the pre-integration complex (PIC) into the nucleus, the final step of integration is not guaranteed. Cellular defense mechanisms may degrade the viral DNA, or the integrase enzyme may fail to catalyze the insertion into a host chromosome. A probability of $0.55$ signifies that nearly half of the PICs that reach the nucleus fail to establish a permanent provirus, making this a critical point of failure in the lentiviral life cycle and thus a strong leverage point on the overall functional titer.\n\nThese two steps, with a combined success probability of $p_{\\text{enc}} \\times p_{\\text{int}} = 0.08 \\times 0.55 = 0.044$, account for a factor of $1/0.044 \\approx 23$ reduction in efficacy by themselves, representing a substantial portion of the total particle-to-TU gap.", "answer": "$$\\boxed{4.34 \\times 10^{9}}$$", "id": "5017554"}, {"introduction": "The promise of permanent genetic correction with integrating vectors is accompanied by the risk of insertional mutagenesis, a critical safety concern in clinical applications. This advanced problem [@problem_id:5017544] challenges you to build a quantitative risk model from first principles, simulating the probability of a harmful clonal expansion event occurring in a patient. By combining principles of Poisson processes with data on vector integration patterns, you will practice the type of probabilistic risk assessment that is essential for evaluating the long-term safety profile of a gene therapy candidate.", "problem": "A clinical program uses integrating lentiviral vectors to modify hematopoietic stem and progenitor cells (HSPCs). Consider a risk model for clonal expansion driven by vector integration adjacent to growth-regulatory genes, constructed from first principles of integration site preferences and Poisson processes. Assume the following scientifically grounded facts and definitions as the base of the model: (i) integration events are independent across cells and across genomic loci, (ii) the number of integrations per cell follows a Poisson distribution characterized by the vector copy number (VCN), (iii) the total number of integrations across independent cells is the superposition of Poisson processes, (iv) integration site selection can be represented as weighted sampling across genomic compartments that differ in chromatin activity, and (v) time to a stochastic expansion event after oncogenic activation follows an exponential distribution with a constant hazard.\n\nYou are given a simplified, genome-wide integration preference model with three compartments:\n- At-risk windows adjacent to growth-regulatory genes (promoter-proximal windows): total length $A$ base pairs with weight $w_{A}$ per base pair.\n- Other active chromatin (excluding the at-risk windows): total length $B$ base pairs with weight $w_{B}$ per base pair.\n- Inactive chromatin: total length $C$ base pairs with weight $w_{C}$ per base pair.\n\nThe total haploid genome size is $L = 3.1 \\times 10^{9}$ base pairs. The fraction of the genome in active chromatin is $f_{\\text{active}} = 0.4$. There are $G = 1000$ growth-regulatory genes, each with an at-risk promoter-proximal window of length $1 \\,\\text{kb}$, so $A = G \\times 10^{3}$. The remaining active chromatin length is $B = f_{\\text{active}} L - A$. The inactive chromatin length is $C = L - f_{\\text{active}} L$. The per-base-pair integration weights are $w_{A} = 8$, $w_{B} = 4$, and $w_{C} = 1$. Under weighted sampling, the probability that a single integration lands in the at-risk windows is\n$$\nP_{\\text{risk}} = \\frac{w_{A} A}{w_{A} A + w_{B} B + w_{C} C}.\n$$\n\nAn infusion contains $N = 5.0 \\times 10^{6}$ engrafting HSPCs. The vector copy number per cell is Poisson with mean $m = 0.5$. Conditional on landing in the at-risk windows, a single integration functionally activates the nearby growth-regulatory gene with probability $q = 1.0 \\times 10^{-4}$. Conditional on such activation, the waiting time to a detectable clonal expansion event is exponential with hazard $h = 0.03 \\,\\text{month}^{-1}$. Over a monitoring horizon of $T = 36$ months, the probability that an activated clone yields a detectable expansion is $1 - \\exp(-h T)$.\n\nAssuming independence of all events across cells and integrations, and using only the principles and facts above, compute the probability that at least one clonal expansion event occurs by time $T$ in this patient. Round your final answer to four significant figures and express it as a unitless decimal.", "solution": "The problem requires the calculation of the probability that at least one clonal expansion event occurs in a patient by a specified time horizon $T$. This can be modeled as a sequence of stochastic events. Let $E$ be the event of at least one clonal expansion. It is most straightforward to calculate the probability of the complementary event, $E^c$, which is that no clonal expansion occurs, and then use the relation $P(E) = 1 - P(E^c)$.\n\nThe problem states that integration events are independent, and the number of events can be described by Poisson processes. The total number of integration events across the $N$ infused cells, where the number of integrations per cell follows a Poisson distribution with mean $m$, also follows a Poisson distribution. Let $K_{\\text{total}}$ be the total number of integrations. The mean of this distribution is the total expected number of integrations, $\\lambda = N \\times m$.\n\nFor each integration event, there is a specific probability that it will lead to a detectable clonal expansion by time $T$. Let this probability be $p_{\\text{event}}$. Since each integration is an independent trial with a constant probability of success $p_{\\text{event}}$, the total number of clonal expansion events, $X$, is the result of a thinning of the total integration Poisson process. Therefore, $X$ also follows a Poisson distribution with a mean $\\lambda_{\\text{expansion}} = \\lambda \\times p_{\\text{event}}$.\n\nThe probability of observing $k$ expansion events is given by the Poisson probability mass function:\n$$P(X=k) = \\frac{\\exp(-\\lambda_{\\text{expansion}}) \\lambda_{\\text{expansion}}^k}{k!}$$\nThe probability of no clonal expansion events ($k=0$) is:\n$$P(E^c) = P(X=0) = \\frac{\\exp(-\\lambda_{\\text{expansion}}) \\lambda_{\\text{expansion}}^0}{0!} = \\exp(-\\lambda_{\\text{expansion}})$$\nTherefore, the desired probability is:\n$$P(E) = 1 - P(E^c) = 1 - \\exp(-\\lambda_{\\text{expansion}})$$\n\nOur task reduces to calculating the mean number of clonal expansion events, $\\lambda_{\\text{expansion}}$. This mean is the product of the mean total number of integrations and the probability that a single integration leads to an expansion.\n$$\\lambda_{\\text{expansion}} = (N \\times m) \\times p_{\\text{event}}$$\nThe probability $p_{\\text{event}}$ is a product of conditional probabilities for a sequence of required events:\n$1$. The integration must occur in an at-risk genomic window, with probability $P_{\\text{risk}}$.\n$2$. Given that it is in an at-risk window, it must functionally activate the gene, with probability $q$.\n$3$. Given activation, the clone must expand to a detectable level by time $T$. The waiting time is exponential with hazard $h$, so this probability is $1 - \\exp(-hT)$.\n\nCombining these, we get:\n$$p_{\\text{event}} = P_{\\text{risk}} \\times q \\times (1 - \\exp(-hT))$$\nAnd so, the full expression for $\\lambda_{\\text{expansion}}$ is:\n$$\\lambda_{\\text{expansion}} = (N \\times m) \\times P_{\\text{risk}} \\times q \\times (1 - \\exp(-hT))$$\n\nWe now proceed to calculate each term using the given values.\n\nFirst, we determine the sizes of the genomic compartments:\n- Total genome size: $L = 3.1 \\times 10^{9}$ bp.\n- Number of growth-regulatory genes: $G = 1000$.\n- At-risk window per gene: $1 \\,\\text{kb} = 10^{3}$ bp.\n- Size of at-risk windows: $A = G \\times 10^{3} = 1000 \\times 10^{3} = 10^{6}$ bp.\n- Fraction of active chromatin: $f_{\\text{active}} = 0.4$.\n- Total active chromatin length: $f_{\\text{active}} L = 0.4 \\times (3.1 \\times 10^{9}) = 1.24 \\times 10^{9}$ bp.\n- Size of other active chromatin: $B = f_{\\text{active}} L - A = 1.24 \\times 10^{9} - 10^{6} = 1.239 \\times 10^{9}$ bp.\n- Size of inactive chromatin: $C = L - f_{\\text{active}} L = (1-0.4) \\times (3.1 \\times 10^{9}) = 0.6 \\times (3.1 \\times 10^{9}) = 1.86 \\times 10^{9}$ bp.\n\nNext, we calculate the probability of integration in an at-risk window, $P_{\\text{risk}}$. This is the ratio of the weighted size of the at-risk compartments to the total weighted size of the genome.\n- Per-base-pair integration weights: $w_A = 8$, $w_B = 4$, $w_C = 1$.\n- Weighted size of compartment A: $w_A A = 8 \\times 10^{6}$.\n- Weighted size of compartment B: $w_B B = 4 \\times (1.239 \\times 10^{9}) = 4.956 \\times 10^{9}$.\n- Weighted size of compartment C: $w_C C = 1 \\times (1.86 \\times 10^{9}) = 1.86 \\times 10^{9}$.\n- Total weighted genome size: $W = w_A A + w_B B + w_C C = 8 \\times 10^{6} + 4.956 \\times 10^{9} + 1.86 \\times 10^{9} = 6.824 \\times 10^{9}$.\n- Probability of an at-risk integration:\n$$P_{\\text{risk}} = \\frac{w_A A}{W} = \\frac{8 \\times 10^{6}}{6.824 \\times 10^{9}} = \\frac{8}{6824} = \\frac{1}{853}$$\n\nNow we assemble all components for $\\lambda_{\\text{expansion}}$:\n- Number of engrafting HSPCs: $N = 5.0 \\times 10^{6}$.\n- Mean vector copy number: $m = 0.5$.\n- Mean total integrations: $N \\times m = (5.0 \\times 10^{6}) \\times 0.5 = 2.5 \\times 10^{6}$.\n- Activation probability: $q = 1.0 \\times 10^{-4}$.\n- Expansion hazard: $h = 0.03 \\,\\text{month}^{-1}$.\n- Monitoring time: $T = 36$ months.\n- Product $hT = 0.03 \\times 36 = 1.08$.\n- Probability of expansion given activation: $1 - \\exp(-hT) = 1 - \\exp(-1.08)$.\n\nWe can now compute $\\lambda_{\\text{expansion}}$:\n$$\\lambda_{\\text{expansion}} = (2.5 \\times 10^{6}) \\times \\left(\\frac{1}{853}\\right) \\times (1.0 \\times 10^{-4}) \\times (1 - \\exp(-1.08))$$\n$$\\lambda_{\\text{expansion}} = \\frac{2.5 \\times 10^{2}}{853} \\times (1 - \\exp(-1.08)) = \\frac{250}{853} \\times (1 - \\exp(-1.08))$$\nNumerically evaluating the terms:\n$$\\frac{250}{853} \\approx 0.2930832356$$\n$$1 - \\exp(-1.08) \\approx 1 - 0.3395958042 \\approx 0.6604041958$$\n$$\\lambda_{\\text{expansion}} \\approx 0.2930832356 \\times 0.6604041958 \\approx 0.19355106$$\n\nFinally, we calculate the probability of at least one event:\n$$P(E) = 1 - \\exp(-\\lambda_{\\text{expansion}}) \\approx 1 - \\exp(-0.19355106)$$\n$$P(E) \\approx 1 - 0.8240215989 \\approx 0.1759784011$$\n\nThe problem requires the answer to be rounded to four significant figures.\nThe value is $0.1759784011...$. The first four significant figures are $1$, $7$, $5$, $9$. The fifth significant figure is $7$, which is greater than or equal to $5$, so we round up the fourth figure.\n$$P(E) \\approx 0.1760$$\nThis is the final probability that at least one clonal expansion event occurs by time $T$.", "answer": "$$\\boxed{0.1760}$$", "id": "5017544"}]}